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IL-17A deficiency promotes periosteal bone
formation in a model of inflammatory
arthritis
Anita T. Shaw, Yukiko Maeda and Ellen M. Gravallese*
Abstract
Background: Interleukin-17A (IL-17A) plays a pathogenic role in several rheumatic diseases including spondyloarthritis
and, paradoxically, has been described to both promote and protect from bone formation. We therefore
examined the effects of IL-17A on osteoblast differentiation in vitro and on periosteal bone formation in an
in vivo model of inflammatory arthritis.
Methods: K/BxN serum transfer arthritis was induced in IL-17A-deficient and wild-type mice. Clinical and histologic
inflammation was assessed and periosteal bone formation was quantitated. Murine calvarial osteoblasts were
differentiated in the continuous presence of IL-17A with or without blockade of secreted frizzled related protein (sFRP)1
and effects on differentiation were determined by qRT-PCR and mineralization assays. The impact of IL-17A on
expression of Wnt signaling pathway antagonists was also assessed by qRT-PCR. Finally, regulation of Dickkopf (DKK)1
expression in murine synovial fibroblasts was evaluated after treatment with IL-17A, TNF, or IL-17A plus TNF.
Results: IL-17A-deficient mice develop significantly more periosteal bone than wild-type mice at peak inflammation,
despite comparable severity of inflammation and bone erosion. IL-17A inhibits calvarial osteoblast differentiation in
vitro, inducing mRNA expression of the Wnt antagonist sFRP1 in osteoblasts, and suppressing sFRP3 expression, both
potentially contributing to inhibition of osteoblast differentiation. Furthermore, a blocking antibody to sFRP1 reduced
the inhibitory effect of IL-17A on differentiation. Although treatment with IL-17A suppresses DKK1 mRNA expression in
osteoblasts, IL-17A plus TNF synergistically upregulate DKK1 mRNA expression in synovial fibroblasts.
Conclusions: IL-17A may limit the extent of bone formation at inflamed periosteal sites in spondyloarthritis. IL-17A
inhibits calvarial osteoblast differentiation, in part by regulating expression of Wnt signaling pathway components.
These results demonstrate that additional studies focusing on the role of IL-17A in bone formation in spondyloarthritis
are indicated.
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Background
Spondyloarthritis is a debilitating disease in which ar-
ticular bone erosion occurs and, in addition, new bone is
formed at periosteal sites around joints where tendons
and ligaments insert, termed enthesophytes. Interleukin-
17 (IL-17) contributes to the pathogenesis of inflamma-
tion in spondyloarthritis. Isoforms A through F comprise
the IL-17 family and both IL-17A and IL-17F are pro-
inflammatory, with IL-17A being more widely studied.
IL-17 induces the expression of proinflammatory cyto-
kines, including tumor necrosis factor (TNF), IL-1, and
IL-6 in stromal cells and macrophages [1, 2], and pro-
motes osteoclastogenesis by upregulating receptor acti-
vator of nuclear factor-κB ligand (RANKL) expression
on osteoblasts and synovial fibroblasts [3, 4]. IL-17A
blockade in inflammatory arthritis has therefore been
shown to limit articular bone erosion [5, 6]. IL-17 pro-
tein levels are elevated in serum from patients with an-
kylosing spondylitis compared to healthy controls [7, 8].
Furthermore, mice that develop experimental enthesitis
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exhibit expansion of lymphocytes that secrete IL-17 [9],
and dendritic cells from HLA-B27 transgenic rats pro-
duce elevated levels of IL-17 from CD4+ T cells, further
supporting a role for IL-17 in inflammation in spondy-
loarthritis [10].
There is controversy over the effects of IL-17A on bone,
and specifically on osteoblast differentiation and function.
Both cortical and trabecular bone in femurs of IL-17A-
deficient and control C57BL/6 mice exhibit similar bone
mineral density, indicating that IL-17A does not signifi-
cantly alter normal skeletal development [11, 12]. Further-
more, bone volume per total volume (BV/TV), osteoclast
number per bone perimeter, and bone formation rate per
bone surface (BFR/BS) are similar in IL-17A-deficient and
control mice [12]. Osteoblasts are derived from mesen-
chymal precursor cells, and human mesenchymal stem
cells (hMSCs) express the IL-17 receptor [13]. Some stud-
ies indicate that IL-17 protects against generalized bone
loss by inducing osteoblast differentiation from hMSCs
[13, 14] and prevents ovariectomy (OVX)-induced bone
loss [15]. Specifically, IL-17 receptor A (IL-17RA)-defi-
cient mice are more susceptible to OVX-induced bone
loss compared to controls and have increased leptin
levels. IL-17 signaling suppresses adipogenesis and pro-
motes osteoblast differentiation from MSCs, suggesting
that IL-17 is bone protective [15]. However, conflicting
studies show that IL-17A blockade or IL-17RA defi-
ciency protects from OVX-induced bone loss [16, 17].
IL-17 also inhibits bone regeneration in a rat model of
calvarial defect [18], providing additional evidence that
IL-17 inhibits osteoblast function.
We therefore sought to determine the effects of
IL-17A on osteoblast function in vitro and on
osteoblast-mediated bone formation in vivo. We took
advantage of the K/BxN serum transfer murine
model of inflammatory arthritis (STA), as it has been
previously demonstrated that although IL-17A is
expressed at low levels, inflammation is not
dependent upon IL-17A in this model [19], allowing
us to compare differences in the impact of inflam-
mation on bone in the presence or absence of IL-
17A. In STA, as in most murine models of inflam-
matory arthritis including collagen-induced arthritis
and antigen-induced arthritis, articular inflammation
results in bone destruction; in addition, however,
periosteal bone formation occurs reproducibly in all
of these models at sites of tendon and ligament
insertions, similar to what is observed in spondyloar-
thritis [20–23]. Thus, STA allows for the direct
examination of the effects of inflammation on
periosteal bone formation in vivo in the absence of
IL-17A.
Here, we demonstrate that IL-17A inhibits osteo-
blast differentiation and modulates the Wnt signaling
pathway in vitro. We further show in vivo that mice
deficient in IL-17A develop increased periosteal new
bone compared to wild-type controls.
Methods
K/BxN serum transfer model of arthritis
Animal procedures were performed in accordance with
protocol A-2262 approved by the IACUC at the Univer-
sity of Massachusetts Medical School. KRN T cell trans-
genic mice (provided by Drs. Benoist and Mathis,
Harvard Medical School and Institut de Genetique et de
Biologie Moleculaire et Cellulaire, Illkirch, France) were
crossed with NOD mice (Jackson) to generate arthritic
K/BxN mice [24, 25]. Arthritogenic serum was prepared
from 9-week-old K/BxN mice. STA was induced in 12-
week-old male IL-17A-deficient mice (Jackson). Absence
of IL-17A expression was confirmed by intracellular
staining (personal communication, Dr. Keiji Hirota).
These mice were backcrossed onto the C57BL/6 back-
ground for six generations and C57BL/6J mice (wild-
type) were used as controls. Arthritogenic serum, 150 μl
per intraperitoneal injection, was administered on days
0, 2, and 7. Ankle thickness was measured as an indica-
tor of inflammation and clinical inflammation was
scored as previously described [26].
Histopathologic analysis
Ankles were fixed in 4 % paraformaldehyde, decalcified
and paraffin-embedded. Fifty 5 μm sections were ob-
tained and every ninth and tenth serial section was
stained with hematoxylin and eosin (H&E) or tartrate re-
sistant acid phosphatase (TRAP) [27] for histopathologic
scoring using previously defined criteria [28].
Quantitation of periosteal new bone formation
Images of H&E stained sections (#10, 30, and 50) were
captured using a Nikon DS-Ri1 camera at the tibia and na-
vicular bones, two sites with reproducible areas of perios-
teal bone formation. Bone formation area was measured
using the NIS-Elements BR software (Nikon). The average
area for each site was calculated for each mouse and sites
were summed to determine total bone formation area. The
average area for each site was then multiplied by 0.2 mm
(the distance through sections 10 to 50) to calculate vol-
ume. In two mice, only 20 slides were available; therefore,
sections #2, 10, and 20 were measured. Total periosteal
bone formation volume for each mouse was determined by
adding the volumes of bone formation from each site.
Murine calvarial osteoblast cultures
Calvarial bones of neonatal (P0) C57BL/6J mice
(Charles River) underwent three sequential digestions
with 0.25 % trypsin (Gibco) and 0.1 % collagenase
(Roche) in α-minimum essential medium (α-MEM,
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HyClone): 8 × 104 cells/well were seeded in 6-well
plates and maintained in α-MEM supplemented with
10 % FBS (Atlanta) at 37 °C, 5 % CO2. At 80 % con-
fluency (day 0), osteoblast differentiation was initiated
with media supplemented with 50 μg/ml L-ascorbic
acid (Sigma) and 10 mM β-glycerophosphate (Sigma)
with 0, 5, or 50 ng/ml recombinant murine IL-17A
(R&D Systems). Samples were performed in duplicate
and media was changed three times a week. Osteo-
blasts were stained with Von Kossa stain using 4 %
silver nitrate (Sigma). For cytokine stimulation, calvar-
ial osteoblasts were treated with or without 50 ng/ml
IL-17A in duplicate on days 7, 14, and 21 of differen-
tiation for 4, 7, or 12 hours. The calvarial osteoblast
experiments were each performed three times using oste-
oblasts from different neonatal mice. Calvarial osteoblasts
were also differentiated in the presence of 50 ng/ml re-
combinant murine IL-17A plus 1 μg/ml rabbit polyclonal
anti-sFRP1 antibody (H-90; Santa Cruz Biotechnology, sc-
13939) or rabbit IgG control (Santa Cruz Biotechnology,
sc-2027). The anti-sFRP1 antibody was selected based on
its effective use at 1 μg/ml in antibody blocking experi-
ments in vitro [29]. Samples were performed in triplicate
(days 7 and 14) or quadruplicate (days 21 and 28) and the
experiment was repeated twice using osteoblasts from dif-
ferent neonatal mice.
Assay for Wnt signaling in osteoblasts
Calvarial osteoblasts were isolated from TOPGAL trans-
genic mice (Jackson) that express a β-galactosidase re-
porter construct responsive to activation of canonical Wnt
signaling, such that expression correlates with Wnt activ-
ity, as determined by the mammalian β-galactosidase assay
kit (Thermo Scientific) with absorbance measurement at
405 nm. Cells were seeded in 96-well plates at 5000 cells/
well. At 80 % confluency (day 0), differentiation media was
added with 7.5 ng/ml recombinant murine TNF (R&D
Systems) or 50 ng/ml IL-17A. β-galactosidase activity was
determined on days 0, 7, 14, 21, and 28 of differentiation.
Murine fibroblast-like synoviocyte (FLS) culture and
cytokine stimulation
FLS were isolated from 8-week-old C57BL/6J mice and
cultured as previously described [30]. Cells were used
between passages 4 and 6: 5 × 104 cells/well were seeded
into 24-well plates in 5 % FBS culture media and treated
in triplicate with or without 10 ng/ml TNF, 50 ng/ml IL-
17A, or a combination of TNF plus IL-17A for 10 or 24
hours. Four independent experiments were performed.
RNA isolation and qRT-PCR
Total RNA was isolated from calvarial osteoblasts using
the RNeasy Mini kit (Qiagen) and RNase-Free DNase set
(Qiagen). Total RNA was isolated from FLS using Trizol
(Ambion) and treated with the Turbo DNA-free kit
(Ambion) to remove contaminating genomic DNA. For
all samples, cDNA was synthesized from 500 ng RNA
using the iScript cDNA synthesis kit (BioRad). qRT-PCR
was performed on samples in duplicate using iScript
SYBR Green RT-PCR mix (BioRad). All primers were
purchased from Qiagen. Gene expression was normal-
ized to the housekeeping gene hydroxymethylbilane syn-
thase (HMBS). Data are expressed as the relative gene
expression in IL-17A-treated compared to untreated
osteoblasts using the 2-ΔΔCt method [31]. For FLS exper-
iments, data are expressed as the relative expression in
IL-17A and/or TNF-treated compared to untreated FLS.
Data represent the mean ± SD.
Osteogenesis PCR array
cDNA was synthesized from 500 ng RNA using the RT2
First Strand Kit (SABiosciences/Qiagen). The RT2 Profiler
PCR Array Mouse Osteogenesis (SABiosciences/Qiagen)
was performed on calvarial osteoblasts cultured with or
without 50 ng/ml IL-17A, assessed at day 28 of differenti-
ation using RT2 SYBR Green ROX qPCR master mix
(SABiosciences/Qiagen). Data were analyzed using the
RT2 Profiler PCR Array Data Analysis web portal
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayana
lysis.php). Data represent the mean ± SD of two inde-
pendent experiments.
Statistical analysis
Prism 6.0 (GraphPad) was used for graphing and stat-
istical analysis. The Mann-Whitney test was used to
calculate the significance of differences between IL-
17A-deficient and wild-type mice in the total volume
of periosteal bone formation. Statistical analysis of
qRT-PCR data was performed using Student’s un-
paired t test to determine the significance of differ-
ences between treated calvarial osteoblasts or FLS and
untreated cells. The mean ± SD of the four independ-
ent FLS experiments is reported, with the exception of
TNF plus IL-17A treatment at 24 hours for one of four
experiments, in which the result was more than three
standard deviations higher than the mean and was
thus considered an outlier. A p value <0.05 was con-
sidered statistically significant.
Results
IL-17A-deficient mice develop increased periosteal bone
in an inflammatory setting
We sought to evaluate the effect of IL-17A deficiency on
bone in STA, an animal model in which both articular ero-
sion and periosteal bone formation reliably occur [20, 23].
IL-17A-deficient and wild-type mice were induced with
STA, and inflammation, bone erosion, and periosteal bone
formation were quantified. IL-17A-deficient and wild-type
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mice developed similar inflammation (Fig. 1a). Histopatho-
logic scoring of H&E-stained and TRAP-stained ankle sec-
tions at peak inflammation (day 10) also revealed a similar
extent of bone erosion at the tibiotalar joint and midfoot
bones (Fig. 1b, c), confirming that IL-17A does not regulate
inflammation or subsequent bone erosion in this inflamma-
tory arthritis model.
The mid and distal tibia and navicular bones are re-
producible sites of periosteal bone formation in STA
(Fig. 1d). Quantitation of periosteal bone volume re-
vealed a statistically significant difference (Fig. 1e, f ) be-
tween IL-17A-deficient and wild-type mice at peak
inflammation (day 10). Quantitation of periosteal bone
area recapitulated these findings (p < 0.05, data not
shown). These data support the hypothesis that IL-17A
may be protective in preventing periosteal bone forma-
tion in an inflammatory setting.
IL-17A suppresses osteoblast differentiation in vitro
The finding that IL-17A deficiency leads to increased peri-
osteal bone formation in vivo led us to further investigate
whether IL-17A directly inhibits osteoblast differentiation.
Calvarial osteoblasts were differentiated in the continuous
presence or absence of IL-17A (5 or 50 ng/ml). IL-17A
inhibited matrix mineralization by mature osteoblasts
(days 21 and 28) at 5 ng/ml and more strikingly at 50 ng/
ml, as indicated by Von Kossa staining (Fig. 2a). qRT-PCR
analysis revealed significant inhibition of expression of al-
kaline phosphatase, a marker of the mid stage of osteo-
blast differentiation, and osteocalcin, a marker of the
mature, mineralizing osteoblast by osteoblasts differenti-
ated in the presence of IL-17A (5 or 50 ng/ml) (Fig. 2b).
Additionally, PCR array analysis confirmed more than 30-
fold decrease in alkaline phosphatase and approximately
225-fold decrease in osteocalcin gene expression in
Fig. 1 IL-17A-deficient mice induced with serum transfer arthritis develop similar inflammation and bone erosion, but increased periosteal bone.
a Clinical inflammation scores and change in ankle thickness in IL-17A-deficient (IL-17A knockout (KO)) and wild-type mice. Values are the mean
± SEM (n = 24 mice per group, days 0–10; n = 12 mice per group, days 11–14). b Representative serial H&E-stained and tartrate-resistant alkaline
phosphatase (TRAP)-stained sections of the navicular bone of IL-17A-deficient and wild-type mice. Scale bar represents 100 μm. c Histopathologic
scoring of inflammation and bone erosion of the ankle and midfoot regions in IL-17A-deficient and wild-type mice at peak inflammation. Each
symbol represents the mean histologic score per mouse (n = 8 mice per group; non-responders with inflammation scores ≤ 0.5 were removed).
Horizontal lines represent the group means. d Schematic of the murine ankle and foot. Red arrows indicate reproducible sites of periosteal bone
formation in serum transfer arthritis (STA) at the mid and distal tibia and navicular bone. e Representative H&E-stained sections of the tibia (left
panels) and navicular bone (middle and right panels) of IL-17A-deficient and wild-type mice. Scale bar represents 100 μm. Arrows indicate areas of
periosteal new bone formation. *Tendon inserting on tibia at site of bone formation. f Quantitation of the volume of periosteal bone formation
at peak inflammation in IL-17A-deficient and wild-type mice. Data represent the mean ± SEM (n = 8 mice per group) (*p < 0.05)
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osteoblasts differentiated in the presence of IL-17A (50
ng/ml) compared to untreated cells at day 28 (Fig. 2c).
These data confirm that IL-17A suppresses calvarial osteo-
blast differentiation and matrix mineralization in vitro.
IL-17A modulates Wnt signaling in differentiating
osteoblasts
Activation of the canonical Wnt signaling pathway is es-
sential for osteoblast differentiation. We therefore hy-
pothesized that IL-17A might suppress osteoblast
differentiation by inhibiting Wnt signaling. We induced
differentiation of calvarial osteoblasts from TOPGAL
mice that express a β-galactosidase reporter construct
responsive to activation of canonical Wnt signaling, in
the presence or absence of IL-17A (50 ng/ml) or TNF
(7.5 ng/ml). Wnt signaling, as indicated by β-
galactosidase expression, was suppressed in osteoblasts
differentiated in the presence of IL-17A (Fig. 3a). TNF
also inhibits osteoblast differentiation [32–34] and as ex-
pected, the continuous presence of TNF during osteo-
blast differentiation inhibited Wnt activity in treated
cells compared to untreated cells (Fig. 3a). These data
support the hypothesis that IL-17A inhibits osteoblast
differentiation by suppressing Wnt signaling.
Fig. 2 IL-17A inhibits differentiation of cultured calvarial osteoblasts. Osteoblasts are differentiated in the presence or absence of IL-17A (5 or 50 ng/ml).
a Representative Von Kossa staining at days 21 and 28 of differentiation (n = 3 independent experiments). b Representative mRNA expression
of alkaline phosphatase and osteocalcin relative to undifferentiated calvarial osteoblasts (day 0) by qRT-PCR over the course of osteoblast
differentiation (n = 3 independent experiments) (*p < 0.05, **p < 0.01, ***p < 0.001 for IL-17A at 5 ng/ml; +p < 0.05, ++p < 0.01, ++++p < 0.0001
for IL-17A at 50 ng/ml). c mRNA expression of alkaline phosphatase and osteocalcin by gene array in mature calvarial osteoblasts at day 28,
differentiated in the continuous presence of IL-17A (50 ng/ml) compared to day 28 control calvarial osteoblasts
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Fig. 3 IL-17A modulates Wnt signaling and expression of Wnt signaling antagonists in calvarial osteoblasts. a Wnt activity, as determined by
β-galactosidase absorbance levels, throughout differentiation of TOPGAL reporter calvarial osteoblasts in the presence or absence of IL-17A (50 ng/ml)
or TNF (7.5 ng/ml). Data represent the mean ± SD (triplicate wells) for each condition (**p < 0.01, ****p < 0.0001 for TNF compared to same-day control;
++p < 0.01, ++++p < 0.0001 for IL-17A compared to same-day control). b Representative secreted frizzled related protein (sFRP)1, sFRP3 and d Dickkopf
(DKK)1 mRNA expression assessed by qRT-PCR in calvarial osteoblasts cultured in the presence or absence of IL-17A (5 or 50 ng/ml) over the course
of differentiation. mRNA expression relative to undifferentiated osteoblasts (day 0) is shown (n = 3 independent experiments) (*p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001 for IL-17A (5 ng/ml); +p < 0.05, ++p < 0.01, +++p < 0.001, ++++p < 0.0001 for IL-17A (50 ng/ml)). c qRT-PCR
showing representative expression of alkaline phosphatase and osteocalcin mRNA in differentiating calvarial osteoblasts cultured in the
presence of IL-17A (50 ng/ml) plus anti-sFRP1 antibody (sFRP1 Ab; 1 μg/ml) or rabbit IgG control (IgG; 1 μg/ml) relative to undifferentiated
cells (day 0) (n = 2 independent experiments) (++p < 0.01, +++p < 0.001, ++++p < 0.0001 for 50 ng/ml IL-17A plus IgG control compared to unstimulated
cells; *p < 0.05, ***p < 0.001 for 50 ng/ml IL-17A plus sFRP1 Ab compared to 50 ng/ml IL-17A plus IgG control). e Representative DKK1 mRNA expression
assessed by qRT-PCR in calvarial osteoblasts (days 7, 14, and 21 of differentiation) treated with IL-17A (50 ng/ml) for 4, 7, or 12 hours. DKK1 expression
relative to untreated osteoblasts (0 hours) is shown (n = 3 independent experiments) (*p < 0.05, **p < 0.01)
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We then sought to identify Wnt pathway components
regulated by IL-17A in osteoblasts in vitro. We per-
formed qRT-PCR to determine mRNA expression levels
of Wnt antagonist sFRP and DKK family members in
calvarial osteoblasts differentiated in the presence or ab-
sence of IL-17A (5 or 50 ng/ml). mRNA expression of
the Wnt signaling antagonist sFRP1 was induced and
mRNA expression of sFRP3 was suppressed by IL-17A
at both 5 and 50 ng/ml (Fig. 3b). As a Wnt antagonist,
the induction of sFRP1 would result in inhibition of
Wnt signaling and inhibited osteoblast differentiation.
Importantly, sFRP3 has been shown to promote osteo-
blast differentiation in bone marrow stromal cells [35].
Therefore, decreased expression of sFRP3 could also re-
sult in inhibition of osteoblast differentiation.
To confirm that the induction of sFRP1 by IL-17A con-
tributes to suppressed osteoblast differentiation, we differ-
entiated calvarial osteoblasts in the presence of IL-17A
(50 ng/ml) plus a blocking antibody to sFRP1 (1 μg/ml) or
control rabbit IgG (1 μg/ml). IL-17A again inhibited
osteoblast differentiation as demonstrated by suppressed
alkaline phosphatase and osteocalcin mRNA expression in
IL-17A-treated osteoblasts plus IgG control compared to
untreated osteoblasts (Fig. 3c). Furthermore, osteoblasts
treated with IL-17A plus anti-sFRP1 antibody exhibited
less suppression of alkaline phosphatase and osteocalcin
mRNA expression compared to IL-17A plus IgG control
(Fig. 3c), demonstrating that blocking sFRP1 diminishes
the inhibition of osteoblast differentiation by IL-17A. In-
hibition was not completely rescued solely by blocking
sFRP1, suggesting that regulation of expression of other
factors modulated by IL-17A, such as sFRP3, may also
contribute to the suppression of osteoblast differentiation.
In contrast, mRNA expression of the Wnt antagonist
DKK1 was inhibited in the continuous presence of IL-17A
(5 or 50 ng/ml) in differentiating calvarial osteoblasts
(Fig. 3d). Cytokines, including IL-1 and transforming
growth factor-β (TGF-β) can exert different effects on
osteoblasts depending upon their stage of differenti-
ation [36]. We thus examined the effect on differenti-
ating calvarial osteoblasts of stimulation with IL-17A
(50 ng/ml) at early, mid and late stages of differenti-
ation. IL-17A decreased DKK1 mRNA expression
levels compared to levels in untreated cells most sig-
nificantly in mature osteoblasts (day 21) after 4, 7, or
12 hours of treatment (Fig. 3e). This decrease in
DKK1 expression would promote Wnt signaling and
osteoblast differentiation.
IL-17A and TNF synergistically induce DKK1 in FLS
Wnt signaling antagonists are also secreted by other cell
types, including FLS, and can act distally on osteoblasts. IL-
17A and TNF exert a synergistic effect in FLS in rheuma-
toid arthritis by increasing the secretion of many factors,
including IL-6, IL-8 and granulocyte-colony stimulating
factor (G-CSF) [1, 37, 38]. We therefore treated murine
FLS with TNF (10 ng/ml), IL-17A (50 ng/ml), or both cyto-
kines in vitro. There was a trend towards increased DKK1
mRNA expression by TNF alone. However, IL-17A plus
TNF synergistically upregulated DKK1 mRNA expression
by approximately fivefold at 10 and 24 hours of treatment
(Fig. 4). There was no effect in FLS on mRNA expression
of the Wnt antagonists sFRP family members, DKK2, or
DKK3 by any treatment (data not shown). The induction of
DKK1 by IL-17A plus TNF in FLS could contribute to in-
hibition of osteoblast differentiation in vivo.
Discussion
Several lines of evidence support IL-17A as a pathogenic
factor that contributes to the inflammatory response in
spondyloarthritis and as a promising therapeutic target
in rheumatic disease [39–41]. Thus, it is important to
understand the impact of IL-17A on bone in an inflam-
matory setting, with specific attention paid to its effect
on bone formation at periosteal and enthesial sites, as
this can lead to significant morbidity and disability in
spondyloarthritis patients. We therefore sought to deter-
mine whether IL-17A has an effect on bone formation at
periosteal sites in the inflammatory setting.
IL-17RA comprises part of the receptor complex for
many IL-17 isoforms including IL-17A and IL-17F. It has
previously been shown that IL-17RA-deficient mice de-
velop less inflammation in the STA model [42], and there-
fore, the effects on bone independent of inflammation
cannot be accurately assessed in IL-17RA deficiency.
However, inflammation is not dependent on IL-17A alone
in the STA model [19], and therefore we chose to study
IL-17A-deficient mice. In this model in which inflamma-
tion leads to both articular bone resorption and periosteal
Fig. 4 Dickkopf (DKK)1 mRNA expression is synergistically induced
by IL-17A plus TNF in fibroblast-like synoviocytes (FLS). DKK1 mRNA
expression by qRT-PCR in FLS treated with IL-17A (50 ng/ml), TNF
(10 ng/ml), or IL-17A plus TNF in combination for 10 or 24 hours.
DKK1 expression relative to unstimulated FLS is shown (average of
n = 4 independent experiments) (**p < 0.01)
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bone formation [20, 23], we demonstrated a significant in-
crease in periosteal bone formation in IL-17A-deficient
mice. There is also evidence for IL-17A acting as an in-
hibitor of osteoblast differentiation in vivo. An IL-17A
blocking antibody alone has been found not to signifi-
cantly affect inflammation in arthritic hTNFtg mice [37].
However, blocking antibodies to IL-17A increase serum
osteocalcin levels, osteoblast number, and bone formation
rates in the tibia, indicating a potential role for IL-17A in
bone formation in the long bones.
IL-17A promotes osteoclastogenesis by inducing pro-
inflammatory cytokines and upregulating RANKL; how-
ever, reports of its effects on osteoblast differentiation
and bone formation are conflicting. We demonstrate
that IL-17A inhibits the differentiation of calvarial osteo-
blasts in vitro. Consistent with our findings, Osta et al.
observed suppressed DKK1 mRNA expression in hMSCs
after 72 hours of treatment with IL-17A, which would
promote Wnt signaling and osteoblast differentiation
[14]. However, after 6 hours of treatment, IL-17A coun-
teracted the TNF-induced increase in the osteogenic
gene bone morphogenetic protein-2 (BMP2), and in
conjunction with TNF, induced expression of Schnurri-3,
an inhibitor of osteoblast differentiation [43]. Taken to-
gether, these data suggest that IL-17A may have differen-
tial effects on osteoblast differentiation depending upon
the state of differentiation of the osteoblast, and the tim-
ing and duration of exposure. In these studies, osteo-
blasts were differentiated from hMSCs, whereas calvarial
osteoblasts were used in our study, which are cells that
are already further along the differentiation stage to-
wards the osteoblast lineage. We observed inhibition of
osteoblast differentiation by IL-17A in vitro, and these
differences could potentially be explained by the use of
different precursor cell populations. Our results are in
agreement with those of Kim et al. who demonstrated
inhibition of differentiation of rat calvarial osteoblasts
after 14 days of culture with IL-17 in vitro and impaired
bone regeneration by IL-17 in a rat model of calvarial
defect [18].
We identify regulation of the Wnt signaling pathway
as one mechanism by which IL-17A may inhibit osteo-
blast differentiation and function, as osteoblasts from
TOPGAL reporter mice differentiated in the presence of
IL-17A exhibited reduced Wnt reporter activity. We
studied the effects of IL-17A on Wnt signaling antago-
nists and found that IL-17A induced sFRP1 and de-
creased sFRP3 expression, both of which would inhibit
osteoblast differentiation. Furthermore, blocking sFRP1
diminished the inhibitory effects of IL-17A on osteoblast
differentiation. DKK1 mRNA expression was, in con-
trast, suppressed in osteoblasts cultured in the presence
of IL-17A. However, IL-17A and TNF synergistically in-
duced DKK1 mRNA expression in FLS, which would be
predicted to inhibit osteoblast differentiation. The in-
hibitory effects of IL-17A on osteoblasts were manifested
in vivo, as IL-17A-deficient mice developed significantly
more periosteal bone in the inflammatory environment.
Patients with spondyloarthritis have excessive bone
formation that can occur at entheses (enthesophytes),
near joints on the periosteal surface (osteophytes), or in
the spine (syndesmophytes). Treatment with non-
steroidal anti-inflammatory drugs reduces radiographic
evidence of spinal progression in spondyloarthritis after
two years of follow up, and long-term treatment with
anti-TNF agents may also provide some protection from
progression of disease as evidenced by imaging studies
[44–46]. Blockade of IL-17A or IL-17RA is a promising
therapeutic approach in patients with spondyloarthritis,
as it decreases IL-17-induced inflammation. In addition,
recent studies demonstrate radiographic evidence of in-
hibition of the progression of joint structural damage in
patients with psoriatic arthritis after a 24-week treat-
ment course with an anti-IL-17A antibody that was
maintained through week 52 [47, 48]. Nonetheless, the
effects of blocking IL-17A on periosteal bone formation
have not yet been evaluated. If IL-17A protects against
bone formation by inhibiting osteoblast maturation,
blocking IL-17A may potentially be detrimental for pa-
tients with spondyloarthritis by promoting and exacer-
bating bony overgrowth. However, periosteal new bone
may not develop if inflammation is well controlled early
on by targeting IL-17A. Our finding that periosteal bone
formation is increased in the absence of IL-17A in an in-
flammatory environment stresses the need for additional
studies of the interplay between IL-17A, control of in-
flammation, and bone formation in spondyloarthritis.
Conclusion
In this report we demonstrate increased bone formation
at periosteal sites in the absence of IL-17A in an in vivo
inflammatory setting. As IL-17A inhibits calvarial osteo-
blast differentiation, we propose that IL-17A may play a
role in limiting bone formation at inflamed periosteal
sites in spondyloarthritis.
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